US Edition
Pulnovo Medical Announces Strategic Investment From Medtronic in Oversubscribed $100 Million Financing Ro
- Pulnovo Medical completed an oversubscribed $100 million financing round led by Medtronic and supported by investors including EQT and OrbiMed.
- Medtronic and Pulnovo have a commercial agreement that includes potential future commercialization opportunities.
- Pulnovo's Pulmonary Artery Denervation System targets cardiopulmonary disease and has been used in about 1,500 procedures worldwide.
- Pulnovo holds FDA Breakthrough Device designation and is conducting two FDA-approved trials led by Dr. Gregg Stone.
44 Articles
44 Articles
The Berkshire Eagle
Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Round
NEW YORK, April 19, 2026 /PRNewswire/ -- Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by Medtronic,…
Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Ro
NEW YORK, April 19, 2026 /PRNewswire/ -- Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100
Medtronic invests in Pulnovo Medical's $100 million round
NEW YORK, April 20, 2026 /PRNewswire/ -- Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by Medtronic, one of the world's largest medical technology companies, alongside continued support from existing investors such as EQT, Qiming Venture Partners, Gaorong Ven…
Coverage Details
Bias Distribution
- 54% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
